INTRODUCTION

S
everal studies demonstrated the efficacy of the B-cell depletion therapy with rituximab (RTX) in RA patients, including those unresponsive to anti-TNF therapy, underlying the important role of B cells in this disease (1) (2) (3) (4) (5) . Several recent papers Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis B cell survival and proliferation (12) , and then its expression may be involved in RTX efficacy. IL-6 exerts its biological activities through interaction with its specific receptor called gp80 or IL-6R alpha on the surface of target cells. The IL-6/IL-6R alpha complex recruits two signal-transducing beta gp130 subunits, leading to the formation of the high-affinity IL-6 receptor complex and finally to signal transduction (13, 14) . The IL6R alpha and beta exist also as soluble forms are generated by either proteolytic cleavage of their membrane moiety or by alternative splicing. The association of IL-6 with the soluble form of IL-6R alpha is capable of eliciting a biological response in cells that express only the membrane gp130. This type of activation, called "trans-signalling", renders virtually all cells capable of responding to IL-6/sIL-6R alpha complexes (15, 16) . Different IL-6 or soluble IL-6R alpha (sIL-6Ra) levels have been described due to specific polymorphisms in IL-6 and IL-6R genes (17) (18) (19) (20) (21) (22) . We here investigated a possible association between RA response to RTX and the -174G>C IL-6, previously associated with different IL-6 serum levels in RA patients (17) .
PATIENTS AND METHODS
Patients
The study was conducted in a real-life retrospective cohort of 142 unselected patients (120 females and 22 males; mean age 60.2±12.9 years) with RA diagnosed according to the ACR classification criteria (23 
Genetic analyses
DNA was extracted by EDTA-treated peripheral blood using an automated methodology (Maxwell 16, Promega, Madison, WI, USA) and dedicated kits (Maxwell 16 Blood DNA purification kit). The analysis of the -174G>C IL-6 promoter polymorphism was made following previously reported methods (19) . Briefly, the followings forward and reverse primers were used: 5'-TGACTTCAGCTT-TACTCTTGT-3' and 5'-CTGATTGGAAACCT-TATTAAG-3'; in a PCR amplification protocol comprising 39 cycles composed by the following 3 steps: 1 minute at 95°C, 1 minute at 55°C, 1 minute at 72°C. PCR products were finally digested with NlaIII (New England Biolabs) and run onto a 3.5% ethidium bromide-stained agarose gel.
Statistical analyses
Chi-square tests for categorical variables and nonparametric t tests for quantitative variables were used using the GraphPad and InStat softwares. Results were considered statistically significant for p£0.05.
RESULTS
Response to RTX at month +6 in the population under study As illustrated in figure 1, a cific therapeutic agent is of high priority and represent also an intriguing challenge for the scientific community. RTX has proved of great efficacy in RA but, as in the case of other biologic agents, response may vary between patients, based also on genetic background. High serum levels of IL-6 are directly correlated with disease activity, RF production, leukocyte infiltration, the severity of joint damage and the systemic manifestations of RA (12, 25) and IL-6 directly favours B cell survival and proliferation, being the most abundant cytokine in the rheumatoid synovium. Recently a significant decrease of IL-6 levels were described in the follow-up of RA patients who respond to RTX (26), but no baseline biological markers were identified to date. In the present study we have shown a significant correlation between the -174G>C IL-6 promoter polymorphism, linked to IL-6 expression level, and response to RTX in RA patients, with comparable results when evaluating the response either by the EULAR and by the ACR criteria.
In accordance with previous studies (24, 27) , positive RF again appeared as a strong positive predictive marker of response to RTX, and this result reinforce those found about the genetic association here observed. Therefore, the analysis of the -174G>C IL-6 promoter polymorphism may be relevant in the evaluation of the RA patient for the choice of RTX therapy.
The main goal of RA therapy is to achieve a good response, instead of a moderate one. In our series, patients carrying the IL6 -174CC homozygosis were very rarely EULAR good responders, if compared to CG/GG -carrying patients (4.8% versus 23.9%), while moderate response was similar in the 2 groups (52.4% and 57%, respectively). Then, based on the present results, a good response to RTX appears very unlikely in patients with RA showing the IL6 -14 CC genotype and thus, treatments different from RTX might be then considered in these patients. Anyway, larger replication studies are needed and still planned by our group to confirm present results. Of note, the same association between poor response to RTX and the IL-6 -174CC homozygosis was seen in the present RA series when subdividing patients as coming from Eastern or Western areas of north Italy (data not shown).
Within-population differences in IL-6 concentration are due both to genetic and environmental influences. Several papers deal with the genetic regulation of IL-6 promoter, and IL-6 gene expression regulation appeared to be affected by complex haplotypes comprising several gene polymorphisms (28) . The -174G>C polymorphism appears as one major determinant and, recently, a large British study on 383 RA patients demonstrated higher IL-6 serum levels in patients with the IL-6 -174CC homozygosis, who were more prone to develop cardiovascular complications (17) . According to these findings, the presence of higher IL-6 serum levels linked to the CC homozygosis of the -174G>C IL-6 polymorphism associate with a poor RTX response in RA. However, when different cytokines were analysed at baseline and in the follow-up of RA patients treated with RTX, no predictive baseline profile was discovered, while a significant decrease of IL-6 and CRP levels was found in patients showing a better response (26) . The decreased IL-6 expression following RTX therapy, rather than the baseline levels, may relate to the degree of response, and serum IL-6 at baseline did not seem to represent a useful tool to predict response to RTX (26) . It is widely known that several unpredictable variables (concomitant drug therapy, concomitant infections, endocrine factors, etc) may affect IL-6 serum levels. Thus, the genetic approach, as we here investigated, should be a more reliable indicator of IL-6 activity. Currently, very few data are available about genetic markers useful, at baseline, to better guide the choice of RTX therapy in RA. We herein provide preliminary evidence of a new possible genetic marker, the CC homozygosis of the -174 IL-6 promoter polymorphism, as a predictor of no response to RTX in RA. This preliminary evidence, if confirmed, may be relevant to optimize the treatment of RA with RTX and other biologic agents (6, 10, 29) . 
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